

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s Phloroglucinol Trimethyl Ether and Dobutamine Hydrochloride have obtained the approvals for registration from the National Medical Products Administration of China (the “NMPA”) to become bulk drugs for the preparations on the market.

Phloroglucinol Trimethyl Ether is mainly used in the preparation of phloroglucinol injection which is mainly used for the treatment of (i) acute spasmodic pain caused by digestive system and biliary dysfunction; (ii) acute spasmodic pain in urethral, bladder and kidney; and (iii) gynecological spasmodic pain. As stated in the Company’s announcement dated 27 August 2024, the Group has obtained the approval for drug production and registration for phloroglucinol injection from the NMPA.

Dobutamine Hydrochloride is mainly used in the preparation of dobutamine hydrochloride injection which is mainly used for heart failure caused by decreased myocardial contractility in organic heart disease, including low-output syndrome following open-heart surgery.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 9 February 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.